| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2165/11592910-000000000-00000 |
| P8608 | Fatcat ID | release_d2iiq7p2kvdmfn7rzr2hzl533i |
| P698 | PubMed publication ID | 21819159 |
| P2093 | author name string | Josep Porta-Sales | |
| Giovambattista Zeppetella | |||
| Frank Elsner | |||
| Ignacio Tagarro | |||
| P2860 | cites work | Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 |
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study | Q33873528 | ||
| The powerful placebo | Q33969075 | ||
| Single-dose pharmacokinetics of fentanyl buccal soluble film | Q34204903 | ||
| Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care | Q34539972 | ||
| Impact and management of breakthrough pain in cancer | Q34975545 | ||
| Pharmacotherapy of cancer-related episodic pain | Q35095194 | ||
| Outcomes in acute pain trials: systematic review of what was reported? | Q35781023 | ||
| Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain | Q35826726 | ||
| Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology | Q36920427 | ||
| Actiq: an effective oral treatment for cancer-related breakthrough pain. | Q36939081 | ||
| The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews | Q37051857 | ||
| Management of breakthrough pain in patients with cancer. | Q37154731 | ||
| The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 | ||
| The role of fentanyl in cancer-related pain | Q37609153 | ||
| Fentanyl pectin nasal spray in breakthrough cancer pain | Q39280365 | ||
| A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain | Q39280743 | ||
| Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain | Q39297474 | ||
| A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial | Q39297854 | ||
| Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes | Q39307077 | ||
| Treating cancer-related breakthrough pain: the oral transmucosal route | Q39330526 | ||
| Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. | Q39331443 | ||
| A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer | Q39344435 | ||
| Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study | Q39372438 | ||
| Clinically important changes in acute pain outcome measures: a validation study | Q39395429 | ||
| Characterization of breakthrough pain by hospice patients and their caregivers | Q39444429 | ||
| Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients | Q39449130 | ||
| Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteers | Q42806008 | ||
| Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. | Q43125350 | ||
| Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study | Q43284157 | ||
| Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension tr | Q43288823 | ||
| Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain | Q44105804 | ||
| Clinical rationale for administering fentanyl to cancer pain patients: two Delphi surveys of pain management experts in Denmark | Q46133853 | ||
| Morphine remains gold standard in breakthrough cancer pain | Q46183060 | ||
| Oral transmucosal fentanyl citrate--OTFC (ACTIQ) #103. | Q46613484 | ||
| Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers | Q48680330 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. | Q51529896 | ||
| Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice | Q74317837 | ||
| P433 | issue | 9 | |
| P921 | main subject | fentanyl | Q407541 |
| opioid | Q427523 | ||
| P304 | page(s) | 605-618 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients | |
| P478 | volume | 31 |
| Q42722974 | Assessment and treatment of breakthrough cancer pain: from theory to clinical practice |
| Q38090468 | Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
| Q35108724 | Development of a lozenge for oral transmucosal delivery of trans-resveratrol in humans: proof of concept |
| Q86955641 | Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON) |
| Q39197889 | Fentanyl Formulations in the Management of Pain: An Update |
| Q46895392 | Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain |
| Q39185838 | Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study |
| Q39476518 | Nasal delivery of fentanyl |
| Q24188053 | Opioids for the management of breakthrough pain in cancer patients |
| Q24202962 | Opioids for the management of breakthrough pain in cancer patients |
| Q34690059 | Pharmacologic management of adult breakthrough cancer pain. |
| Q53681112 | Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. |
| Q91736316 | Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain |
| Q37053311 | Single-dose fentanyl sublingual spray for breakthrough cancer pain |
| Q39181576 | Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes |
| Q38001278 | The management of pain in metastatic bone disease |
| Q55077608 | Prise en charge pharmacologique de la douleur cancéreuse paroxystique chez l’adulte. |
Search more.